Comparing Oral and Transdermal Estrogen Therapy
Female sexual dysfunction (FSD) is commonly associated with declining estrogen levels around the menopausal transition. At least 23% of naturally menopausal women are distressed by their low sexual desire, thus the US Food and Drug Administration has recently identified FSD as a serious condition with unmet needs as part of its program on patient-oriented drug development. Recently, researchers published a study in JAMA comparing an oral and transdermal estrogen therapy on their efficiency at increasing sexual function in early postmenopausal women.
Although many previous studies revealed that treatment with estrogens alone or in combination with progesterone improved sexual function, there has not been any direct comparison on route nor composition of estrogens. The ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS) aims to do just that, by comparing oral and transdermal estrogen therapy. The ancillary study is a four-year prospective, randomized, double-blinded, placebo-controlled trial of menopausal hormone therapy in healthy, recently menopausal women. Data were collected from July 2005 through June 2008 and analyzed from July 2010 through June 2017.
Read more from Medical News Bulletin, by Christine Gibson, Comparing Oral and Transdermal Estrogen Therapy